null

null

null

null

null

null

null

null

null

null

null

null

null

null

Near-zero long-term debt; company is pre-revenue/early-stage biotech funded primarily by equity raises and grants; minimal debt service obligations.

Negligible direct interest rate sensitivity; no significant floating-rate debt; higher rates increase cost of future equity dilution as investor hurdle rates rise.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Israeli manufacturing/R&D concentration amid Middle East geopolitical risk; 2) single-source biological raw material suppliers, likely European or US-based API providers.

Revenue is grant/milestone-based, primarily in USD/EUR/ILS; ILS devaluation vs USD poses moderate risk to Israeli operational costs; limited direct currency revenue exposure.

Operations centered in Israel; revenues denominated mainly in USD and EUR via partnerships; exposed to ILS/USD volatility for operating cost base in Israel.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency risk: single CRO/CMO relationships for BiondVax-derived nanobody platform manufacturing likely represent non-substitutable operational inputs exceeding 30% of costs.

Cloud disruption risk is low-moderate; core IP is biology/laboratory-based; digital operations could migrate but regulatory data and lab systems are not cloud-critical.

Secondary digital operations (clinical data management, regulatory submissions) could face 60-90 day disruption; no proprietary cloud-native product dependent on single provider.

Moderate API coupling risk; uses standard bioinformatics and CRO platforms; no deep proprietary API lock-in, but switching CMO partners mid-trial is costly and time-consuming.

Low Howey Test risk; revenue model is milestone payments and grants from pharma partners, not investment contracts; equity is registered securities, not tokens.

Very High

Moderate GDPR exposure via EU clinical trial patient data; CCPA exposure minimal given no consumer-facing product; Israeli PDPL compliance required for domestic operations.

Negligible antitrust risk; small-cap biotech with no market dominance; nanobody platform occupies niche segment with multiple competing platforms.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/milestone-based; no recurring subscription revenue; dependent on partner milestone achievements and government/EU grant disbursements.

Licensing milestones, research grants (EU Horizon, BARDA-type), and potential royalties on partnered nanobody therapeutics; no direct product sales currently.

No commercial pricing architecture yet; licensing deal terms set by negotiation with large pharma partners; weak standalone pricing power as early-stage licensor.

Low pricing power; company is price-taker in licensing negotiations with larger pharma; differentiated nanobody IP provides some leverage but insufficient clinical data limits negotiating strength.

Target gross margin 70-85% on licensing/royalty revenue if commercialized; current gross margin undefined due to pre-commercial stage and grant-offset R&D costs.

No free-rider problem; IP-protected platform; primary risk is partner program cancellation (single-partner churn could eliminate >50% of expected milestone revenue).

Headcount-sublinear at scale; nanobody platform is IP/technology licensing model; doubling revenue via additional licensing deals requires minimal incremental headcount.

Marginal cost of growth is low for licensing revenue; incremental deals require BD and legal resources, not proportional lab scale-up; manufacturing outsourced to CMOs.

Not applicable; no franchise network.

At 10x scale, CAC remains relationship-driven pharma BD; cost per partnership deal likely $500K-$2M in BD/legal spend; LTV depends on royalty streams worth hundreds of millions.

No meaningful network effects; nanobody platform value is intrinsic to IP and clinical outcomes, not user/partner network size.

AI displacement risk is low-moderate; AI accelerates nanobody discovery and screening but does not replace proprietary BiondVax platform IP or regulatory knowhow.

Moderate recession resistance; pharma R&D budgets contract in severe downturns, threatening milestone payments; grant funding is relatively stable counter-cyclically.

Large and mid-size pharmaceutical/biotech companies seeking nanobody-based therapeutic candidates via licensing or co-development partnerships.

Government and supranational grant agencies (EU Horizon, potential US BARDA/NIH) funding infectious disease and respiratory therapeutic research.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital reallocation toward asset-light model; divested vaccine operations post-BiondVax merger restructuring; capex focused on nanobody platform R&D, not legacy infrastructure maintenance.

0001611747

SCNI